The Effects of an 8-week Vegan Diet on Trimethylamine-N-Oxide (TMAO) Levels and Post-challenge Glucose Levels in Individuals With Dysglycaemia (The Plant Your Health Study)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Change from Baseline TMAO plasma levels at 1, 8 and 12 weeks.
研究概览
简要总结
The amount of people with diabetes mellitus has now reached over 4 million in the United Kingdom. Type 2 diabetes accounts for the majority of all cases of diabetes and increases the risk of many other diseases such as heart problems. Plant based diets are thought to be an effective way to improve markers of health related to type 2 diabetes and heart disease. One way that a plant based diet improves health could be through reducing waste products that are generated in the gut by the bacteria that break down food as part of the digestion process. For example, the digestion of some meats, fish and eggs results in the creation of a substance called Trimethylamine-N-Oxide (TMAO) which has been linked to worse health outcomes in several studies. However, the full impact on TMAO and blood glucose levels of swapping regular meat consumption for a plant based vegan diet is not fully understood and requires further research. Therefore, the aim of this study will be to develop and undertake a clinical trial to investigate the effects of an 8-week vegan diet on TMAO levels and post challenge glucose levels in individuals with dysglycaemia (drug naïve).
The study will be interventional single group prospective trial of adults aged 18-75 years of age from a multi-ethnic population with dysglycaemia (drug naïve). A sample of 29 people will be sought. The dietary intervention (vegan diet) will last 8 weeks. Then, the participants will go back to their normal diet and come for their final visit after a four week follow-up period (week 12). To assess the effectiveness of the intervention, primary and secondary outcome data collected at baseline will be compared with data collected at 1 week, 8 weeks and 12 weeks.
详细描述
Study Design
Interventional single group prospective trial in a patient population with identified dysglycaemia within the past 36 months defined as 2h post-challenge glucose ≥7.8 mmol/L after a standard oral glucose tolerance test or HbA1c ≥5.7% (39-46 mmol/mol). This phase clinical trial will evaluate the efficacy and underlining mechanisms of a vegan diet in promoting cardiometabolic health in those with dysglycaemia. Specifically, this trial will aim to investigate the effect of an 8-week vegan diet with follow-up at 1, 8 and 12 weeks.
Study Setting
The study will be co-ordinated within the Leicester Biomedical Research Centre (Leicester Diabetes Centre) at the Leicester General Hospital. Clinical measurement sessions will be carried out by the appointed research team. Participants will be asked to visit the study centre on five occasions.
Intervention Description and Definition
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant is willing and able to give informed consent for participation in the study
- •And either:
- •Overweight (White: BMI>25 - <30, South Asian/ Black and minority ethnic group <27.5) with HbA1c between HbA1c ≥5.7% and ≤ 8% (39-64 mmol/mol) identified within the last 36 months
- •Obese: (White: BMI ≥30, South Asian/ Black and minority ethnic group: ≥27.5)
- •Male or Female
- •Aged 18 - 75 years inclusive
- •Able to understand, read and speak the English language to a sufficient level to understand and take part to the study in the investigators opinion
- •Have access to a phone, and willing to use it as part of the study
- •Regular meat and/or fish eater (at least 3 times per week)-self reported
排除标准
- •Participant is unwilling or unable to give informed consent
- •Non-English speakers
- •HbA1c above 8% (64 mmol/mol)
- •Taking any form of glucose lowering medication currently or within the last 60 days
- •Current smokers
- •Current use of vegan or vegetarian diet
- •Recent significant weight change (10% or more) over the last 3 months
- •Pregnancy/lactation
- •Clinical eating disorder as detected by their GP or relevant health professional (e.g. dietitian)
- •Have a terminal illness
- •Current or recent (within 6 months) oral antibiotics or steroid use as their usage could impact on the gut bacteria profile
- •Ongoing CVD (e.g. angina) *
- •In the circumstance that an individual is not sure whether they meet the inclusion/ exclusion criteria, (i.e. they are not sure if they have ongoing CVD) this will be reviewed by a named medic on the delegation of authority log for a clinical decision to be made during baseline.
结局指标
主要结局
Change from Baseline TMAO plasma levels at 1, 8 and 12 weeks.
时间窗: at 1 (+ 5 days) week , 8 (+/- 5 days) weeks and 12 weeks (+/- 5 days)
urine and plasma samples for TMAO (μM)
Change from Baseline 3-hour post-challenge glucose levels at 1, 8 and 12 weeks.
时间窗: at 1 (+ 5 days) week , 8 (+/- 5 days) weeks and 12 weeks (+/- 5 days)
blood samples (mmol/l)
次要结局
- TMAO (μM) urine levels at baseline.(at baseline)
- Change from Baseline in TMAO urine/plasma levels at 1 week following a vegan diet.(at 1 week (+ 5 days))
- Change from Baseline 3-hour post-challenge glucose levels at 1 week following a vegan diet.(at 1 week (+ 5 days))
- Change from week 8 in TMAO urine/plasma levels at 4 weeks after diet has returned to normal (week 12).(at 12 weeks (+/- 5 days))
- Change from week 8 in 3-hour post-challenge glucose levels at 4 weeks after diet has returned to normal (week 12).(at 12 weeks (+/- 5 days))
- Change from Baseline in body composition using dual energy X-ray absorptiometry (DXA) scan at 8 weeks following a vegan diet.(at baseline and week 8 (+/- 5 days))
- Change from Baseline in biochemical measures of cardiometabolic health including post-challenge insulin at 1 week.(1 week (+5 days))
- Change from Baseline in biochemical measures of cardiometabolic health including post-challenge insulin at 8 weeks.(8 weeks (+/- 5 days))
- Change from Baseline in biochemical measures of cardiometabolic health including post-challenge insulin at 12 weeks.(12 weeks (+/- 5 days))
- Change from Baseline in biochemical measures of cardiometabolic health including fasting lipids and at 1 week.(1 week (+5 days))
- Change from Baseline in biochemical measures of cardiometabolic health including fasting lipids and inflammatory markers at 8 weeks.(8 weeks (+/- 5 days))
- Change from Baseline in biochemical measures of cardiometabolic health including fasting lipids at 12 weeks.(12 weeks (+/- 5 days))
- Change from Baseline in biochemical measures of cardiometabolic health including inflammatory markers at 1 week.(1 week (+5 days))
- Change from Baseline in biochemical measures of cardiometabolic health including inflammatory markers at 8 weeks.(8 weeks (+/- 5 days))
- Change from Baseline in biochemical measures of cardiometabolic health including inflammatory markers at 12 weeks.(12 weeks (+/- 5 days))
- The extent to which changes in the primary outcomes are mediated by, or independent of, changes to body composition.(week 8 (+/- 5 days))
- The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors.(weeks 1-12)
- Semi-structured interviews with the completers, at the end of the study, to investigate perception responses having been on a vegan diet.(at week 12 (+/- 5 days))